Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism
Samuel Frey(Centre National de la Recherche Scientifique), Claire Blanchard(Centre National de la Recherche Scientifique), Éric Mirallié(Centre Hospitalier Universitaire de Nantes), Edith Bigot‐Corbel(Centre Hospitalier Universitaire de Nantes), Mikaël Croyal(Centre National de la Recherche Scientifique), Bertrand Cariou(Institut du Thorax), C. Caillard(Centre Hospitalier Universitaire de Nantes), Cédric Le May(Centre National de la Recherche Scientifique), Matthieu Wargny(Centre National de la Recherche Scientifique), Raphaël Bourgade(Inserm), Nelly Renaud-Moreau(Centre Hospitalier Universitaire de Nantes)
Cited by 13
Related Papers
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
|The Lancet Diabetes & Endocrinology|2017|439
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
|Diabetes Care|2019|282
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
|Diabetes & Metabolism|2019|281
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
|The Journal of Clinical Endocrinology & Metabolism|2020|147